- Open Access
NAAG peptidase inhibition in the periaqueductal gray and rostral ventromedial medulla reduces flinching in the formalin model of inflammation
Molecular Pain volume 8, Article number: 67 (2012)
Metabotropic glutamate receptors (mGluRs) have been identified as significant analgesic targets. Systemic treatments with inhibitors of the enzymes that inactivate the peptide transmitter N-acetylaspartylglutamate (NAAG), an mGluR3 agonist, have an analgesia-like effect in rat models of inflammatory and neuropathic pain. The goal of this study was to begin defining locations within the central pain pathway at which NAAG activation of its receptor mediates this effect.
NAAG immunoreactivity was found in neurons in two brain regions that mediate nociceptive processing, the periaqueductal gray (PAG) and the rostral ventromedial medulla (RVM). Microinjection of the NAAG peptidase inhibitor ZJ43 into the PAG contralateral, but not ipsilateral, to the formalin injected footpad reduced the rapid and slow phases of the nociceptive response in a dose-dependent manner. ZJ43 injected into the RVM also reduced the rapid and slow phase of the response. The group II mGluR antagonist LY341495 blocked these effects of ZJ43 on the PAG and RVM. NAAG peptidase inhibition in the PAG and RVM did not affect the thermal withdrawal response in the hot plate test. Footpad inflammation also induced a significant increase in glutamate release in the PAG. Systemic injection of ZJ43 increased NAAG levels in the PAG and RVM and blocked the inflammation-induced increase in glutamate release in the PAG.
These data demonstrate a behavioral and neurochemical role for NAAG in the PAG and RVM in regulating the spinal motor response to inflammation and that NAAG peptidase inhibition has potential as an approach to treating inflammatory pain via either the ascending (PAG) and/or the descending pain pathways (PAG and RVM) that warrants further study.
Each of the current analgesic therapies has limited efficacy in treating inflammatory and neuropathic pain and some have significant side effects. As a result, there is a need to develop drugs with different targets in the nociceptive processing pathway. The heterotropic group II metabotropic glutamate receptor (mGluR2 and mGluR3) agonists have shown analgesic efficacy in animal models of inflammatory and neuropathic pain . Consistent with this, activation of the type 3 metabotropic “glutamate” receptor (mGluR3) by the peptide neurotransmitter N-acetylaspartylglutamate (NAAG) reduces the flinching response to peripheral inflammation, reduces hyperalgesia induced by peripheral neuropathy and moderates the pain response in a model of bone cancer [2–9].
NAAG is one of the most prevalent transmitters in the mammalian nervous system . It activates presynaptic mGluR3 receptors resulting in reductions in cAMP and cGMP levels [11–15], reduction in depolarization-induced calcium influx and inhibition of transmitter release [16–20]. The enzymes that inactivate synaptically released NAAG have been cloned [21–25] and potent inhibitors of these enzymes have been developed [26, 27]. Systemic administration of these inhibitors, including ZJ43, reduces pain responses in animal models [2, 4–9, 28, 29].
This research aimed to provide further insight into the mechanism of NAAG’s action in the pain processing pathway. We directly tested the hypothesis that the analgesic-like effects of NAAG peptidase inhibition in the formalin model of inflammation are mediated centrally in two well-recognized regions of the ascending and descending pain pathways, the periaqueductal gray (PAG) and the rostral ventromedial medulla (RVM). In parallel, the efficacy of systemically administered ZJ43 in elevating extracellular NAAG levels was assessed in these brain regions as was the influence of NAAG on the levels of inflammation-induced glutamate release.
Using highly specific, multi-stage affinity purified antibodies (see Methods), NAAG immunoreactivity was observed in neurons and axons in the rat PAG and RVM (Figure 1a,b). Consistent with the potential of this transmitter to regulate neurotransmission via activation of presynaptic receptors in these brain regions, putative NAAGergic synapses were observed on the cell bodies and dendrites of PAG neurons, as well as in the neuropil (Figure 1c). While these data alone are insufficient to confirm the synaptic localization of this immunoreactivity, studies with this antibody at the ultrastructural level previously localized NAAG immunoreactivity to synaptic vesicles  and optic nerve transection studies demonstrated that NAAG immunoreactivity is associated with NAAG-containing synaptic terminals in various regions of the CNS [31, 32]. Additionally, depolarization-induced calcium-dependent NAAG release has been demonstrated repeatedly [10, 33]. These data on the presence of NAAG in the PAG and RVM provided a rationale for microinjection of the NAAG peptidase inhibitor ZJ43 into these regions of the pain transmission pathway.
Subcutaneous injection of formalin in the rat footpad produced a reliable biphasic display of flinching of the injected paw (Figure 2) consistent with our previous studies [6–8]. Microinjection of ZJ43 (150 μg) into the PAG contralateral to the inflamed footpad significantly decreased the number of flinches in both the early and late phase. These effects of ZJ43 were dose-dependent (Figure 3) and blocked by i.p. injection with the mGluR2/3 receptor antagonist LY341495 (Figure 4, p < 0.05). We previously found that systemic injection of this antagonist alone had no significant effect on the response in the formalin or sciatic nerve ligation tests although a ceiling affect in the former and floor effect in the latter could have precluded detecting a change in response [6–8, 29]. To confirm the restricted distribution of the peptidase inhibitor from the injection site, particularly its close proximity to the aqueduct, ZJ43 was injected into the PAG ipsilateral to injected footpad. The ipsilateral injection response was significantly different from the response following contralateral PAG injection (Figure 5, Phase 1: ipsilateral, 36.4 ± 6.5; contralateral, 12.7 ± 2.1, p < 0.005; Phase 2: ipsilateral, 136 ± 21.5; contralateral, 79.4 ± 7.8, p < 0.05) and not significantly different from the response following saline injection into the contralateral PAG (Phase 1: 34.7 ± 5.5; Phase 2: 156 ± 15.6).
NAAG-like immunoreactivity was found in the RVM, including the nucleus raphe magnus (Figure 1b). Microinjection of ZJ43 (150 μg) into the RVM also significantly reduced flinching in the rapid (p < 0.001) and slow (p < 0.01) phases of the inflammatory pain response (Figure 6a, b). The mGluR 2/3 antagonist LY341495 (i.p.) again reduced the effect of the peptidase inhibitor on the first phase of the flinching response (p < 0.05) and blocked the effect in the slow phase (p < 0.01) (Figures 6a, b). ZJ43 was effective in a dose-dependent manner (p <0.05) in both phases of the flinching response (Figure 7).
Consistent with our previous reports that systemically administered ZJ43 and 2-PMPA failed to affect the thermal response latency [3, 4], microinjection of ZJ43 (150 μg) into the PAG or RVM had no effect on the response in the hot plate test (Figure 8).
Our model of the efficacy of NAAG peptidase inhibition [3, 33] predicts that ZJ43 will increase the extracellular levels of the peptide that in turn will activate presynaptic mGluR3 receptors to reduce release of glutamate or other transmitters. To test this, ZJ43 (150 mg/kg) was injected (i.p.) 15 minutes prior to footpad inflammation. This i.p. dose previously has been shown to reduce both the rapid and slow phase of the flinching response . NAAG and glutamate levels were assessed by microdialysis in the PAG and RVM.
Formalin injection had no effect on NAAG levels in PAG and RVM (Figure 9a, b). ZJ43 increased NAAG levels by ~20-fold. There was a significant difference in NAAG levels between groups in the 0–140 min PAG dialysate samples (p < 0.01), and an overall time × group interaction was observed for NAAG in PAG (F6, 36 = 7.711, p < 0.001). There was a significant difference in NAAG levels between groups in the 0-140 min RVM dialysate sample (p < 0.001) and an overall time × group interaction was observed for NAAG in RVM (F6, 60 = 24.368, p < 0.001).
Formalin injection into the footpad resulted in a 40% increase in glutamate release over baseline in the contralateral PAG between 5 and 25 minutes after the inflammatory insult (Figure 10a). Systemic injection of ZJ43 (150 mg/kg, i.p.) blocked this increase in glutamate release as our model predicted. There was a significant difference in glutamate levels between groups in the 20–40 min dialysate sample (p < 0.05), and an overall time × group interaction also was observed for glutamate (F2, 16 = 5.57, p < 0.05). In the contralateral RVM, there was a small and not statistically significant increase in glutamate release in response to footpad inflammation and this was unaffected by systemic ZJ43 treatment (Figure 10b). The use of a smaller dialysis probe (1 mm vs 2 mm) similarly showed no effect of inflammation on glutamate levels in the RVM.
Current analgesic therapies typically inhibit cyclooxygenase enzymes or activate opiate receptors. Each of these front line analgesics for treatment of inflammatory and neuropathic pain has some negative clinical consequences or lacks efficacy in a significant proportion of patients. Adjuvant analgesics, including antidepressants (SSRIs), anticonvulsants (gabapentin, pregabalin) and anesthetics (mexiletine, lidocaine) are sometimes effective in relieving pain. However, they do not represent widely effective treatments for relief of chronic inflammatory or neuropathic pain or hyperalgesia.
The NAAG receptor, mGluR3, is widely expressed by neurons and glia in the nervous system including the PAG and RVM . The observation of NAAG immunoreactivity (Figures 1a–c) in the ascending and descending pain pathway supports the potential of NAAG peptidase inhibitors to affect the response to inflammation.
The efficacy of NAAG peptidase inhibition in the PAG is consistent with the report that intra-PAG injection of the group II mGluR agonist L-CCG-I also reduces responses in the formalin model . In previous studies, we found that peripheral , intrathecal  and intracerebroventricular  administration of NAAG peptidase inhibitors had similar analgesia-like properties in the formalin test. The data in this manuscript provide the first insight into the potential of NAAG and the inhibitors of its inactivation to influence the ascending (PAG) and descending (RVM and PAG) pain pathways. Given the expression of mGluR3 receptors and NAAG in the spinal cord and spinal sensory neurons [10, 33], our previous studies and the data presented here suggest that, like opiate peptides, NAAG has the potential to moderate the response to inflammatory pain at several different levels within this pathway. The efficacy in this model of NAAG peptidase inhibition in the PAG and RVM support the conclusion that, at a minimum, the release of NAAG in these regions modulates the spinal pain response via the descending inhibitory pain pathway. This hypothesis needs to be further tested in other models that more clearly assess perception of pain since flinching in the formalin model can be critiqued as a spinal reflex that does not reflect cortically based cognition of pain. Relevant to this question, we previously reported that systemic and intrathecal injections of two NAAG peptidase inhibitors were highly effective in the sciatic nerve ligation and carrageenan pain models [5, 6]. Additionally, we found NAAG peptidase inhibition to be analgesic in a model of bone cancer pain .
A series of studies demonstrate that NAAG peptidase inhibition elevates extracellular NAAG levels with the consequent activation of a group II mGluR (mGluR3), an activity that inhibits the release of small amine transmitters including glutamate, GABA, and aspartate, via presynaptic inhibition [16–20]. While other mechanisms of action are possible, presynaptic inhibition might well be responsible for the efficacy of NAAG peptidase inhibitors in animal models of several nervous system disorders .
Figure 10a presents the first demonstration of inflammation-induced increase in glutamate release in the PAG, a result consistent with increased ascending excitatory signals from the site of inflammation. Given the efficacy of ZJ43 microinjection into the PAG in reducing flinching and increasing extracellular NAAG levels, we examined the effect of NAAG peptidase inhibition on this inflammation-induced glutamate release. Systemically applied ZJ43 (50 mg/kg) reaches a concentration of 2 nM in the brain 30 minutes after injection  and significantly reduces NAAG hydrolysis in the rat brain in vivo (Olszewski et al., submitted). Its efficacy in blocking this inflammation-induced glutamate release in the PAG is consistent with our models of NAAG activation of presynaptic mGluR3 to inhibit transmitter release [3, 33]. The difference between the RVM and PAG with respect to formalin-induced glutamate release could reflect the role of the PAG, but not the RVM, in the ascending pain pathway. While these data demonstrate a role for NAAG in the control of inflammation-induced glutamate release in the PAG, they are not sufficient to prove that the NAAG peptidase inhibition-mediated decrease in glutamate release mediates the observed reduction in the inflammation-induced motor response.
Microinjection of ZJ43 into the RVM also reduced the response to footpad inflammation (Figures 6 7) and systemic treatment with this inhibitor also elevated RVM NAAG levels (Figure 9b). In contrast to the PAG, however, inflammation did not significantly elevate glutamate levels in the RVM. Since microinjection of excitatory amino acids into the RVM is analgesic , it would not be expected that formalin treatment would necessarily produce a substantial increase in glutamate release or that inhibition of glutamate release in the RVM would mediate analgesia. One interpretation of these data is that NAAG activation of mGluR3 receptors inhibited the release of other transmitters in the RVM with the consequent effect on the local circuitry [37, 38]. For example, inhibition of GABA release could indirectly result in an increase in release of other transmitters, whose actions mediate analgesia in the RVM [39, 40]. Alternatively, the effect of formalin injection on glutamate release in the RVM might have been restricted to a volume of tissue that was smaller than that sampled by the microdialysis probe resulting in a failure to detect increases in glutamate levels above the background in the sampling area. However, a small study (n = 3) obtained using a smaller (1 mm) dialysis probe tip in sampling the RVM provided no evidence of an inflammation stimulated increase in glutamate release Figure 10b.
Heterotropic group II mGluR (mGluR2 and mGluR3) agonists reduce inflammatory pain responses and also may represent a novel analgesic strategy . However, these compounds were tested in mGluR2 and mGluR3 knockout mice in animal models of schizophrenia and were found to be effective in mGluR3 but not mGluR2 knock outs [41, 42]. In the same animal models, NAAG peptidase inhibition was effective in the mGluR2 but not the mGluR3 knockout mice . These data support the conclusion that the heterotropic mGluR2/3 agonists and mGluR2 positive allosteric modulators have the potential to be effective mGluR2 based analgesic strategies in contrast to NAAG peptidase inhibition that represents an mGluR3 specific strategy. Also relevant to the differences between these two analgesic approaches, pharmacotherapies, such as antidepressants, sedatives and anxiolytics, that increase the activity of endogenous transmitters tend to enhance the normal ongoing physiology and thus can have less potential for secondary effects than continuous agonist-based receptor activation.
The concept that orally available NAAG peptidase inhibitors [2, 26] might ultimately be used clinically for the treatment of inflammatory and neuropathic pain begs the question as to their potential secondary effects inasmuch as the peptide and mGluR3 are widely distributed in the nervous system. Studies in mice do not suggest that negative secondary effects result from NAAG peptidase inhibition . For example, we found no significant neurological deficits in mice in which the major NAAG peptidase, glutamate carboxypeptidase II, had been knocked out . Similarly, chronic treatment with a NAAG peptidase inhibitor was without detectable side effects in a study where the drug increased the lifespan of mice in a model of amyotrophic lateral sclerosis . Acute treatment with ZJ43 similarly lacks detectable effects in open field behavior , prepulse inhibition of acoustic startle , or the 1.5 hr delay novel object recognition test [Olszewski et al., submitted]. Neither systemic NAAG peptidase inhibition  nor microinjection of 150μg of ZJ43 into the PAG and RVM (Figure 8) alter the reaction time of rats in the hot plate test. This lack of apparent side effects is consistent with the established pattern of peptide co-transmitter release under conditions of high neuronal activity with little released during normal to low levels of activity. Consistent with this concept, the basal extracellular concentrations of NAAG and glutamate in the dialysates, uncorrected for recovery, were 53 ± 06 nM and 1,250 ± 130 nM in PAG, 74 ± 5 nM and 820 ± 70 nM in RVM respectively. This difference in extracellular concentrations also is found in other brain regions [19, 20] despite the fact that NAAG is present in mM concentrations in the mammalian nervous system . Such a pattern of release is consistent with our model of NAAG feeding back on presynaptic mGluR3 to dampen synaptic release of primary amine transmitters under conditions of high activity .
The data presented here provide the first demonstration of: 1) the presence of NAAG within neurons and presumptive synaptic endings in two discrete regions of the pain processing pathway of the brain, the PAG and RVM; 2) the elevation of synaptically released NAAG in these sites by systemic application of a NAAG peptidase inhibitor; 3) the analgesic efficacy of NAAG peptidase inhibition directly in the PAG and RVM; 4) the role of the mGluR3 receptor in mediating the analgesic efficacy NAAG peptidase inhibition in the PAG and RVM based on NAAG’s selectivity for this receptor  and the blockade of the effect NAAG peptidase inhibition by co-administration of the mGluR2/3 antagonist LY431495. These data support the conclusion that NAAG peptidase inhibition has potential as an approach to treating inflammatory pain via either the ascending (PAG) and/or the descending pain pathways (PAG and RVM) and warrants further study.
Materials and methods
The Institutional Animal Care and Use Committees at Georgetown and Kumamoto University approved all animal procedures. The principles of animal care were consistent with the standards of the US National Institutes of Health and Department of Agriculture. Male Sprague–Dawley rats (300–350 g) were housed in groups of two, maintained on a 12-hour dark–light cycle, and permitted food and water ad libitum. Animals were handled on arrival and were housed for at least three days before testing. Behavioral testing was performed between 10.00 h and 16.00 h. Animals were euthanized immediately after behavioral or microdialysis studies.
Immunohistochemistry and antibodies
The NAAG specific antisera were prepared and immunohistochemistry performed as previously described [48, 49]. Briefly, polyclonal NAAG antisera were purified in stages by both affinity chromatography and negative-affinity adsorption against related protein-coupled molecules including N-acetylaspartate N-acetylglutamate glutamate, aspartate and GABA . Rats were transcardially perfused with 6% carbodiimide and 5% DMSO. Brains were post fixed with 4% paraformaldehyde, saturated with 30% sucrose, frozen and sectioned (20 μm). Sections were treated with 2% normal goat serum prior to incubation with affinity purified anti-NAAG rabbit serum (1:2,000). Antibodies were visualized with peroxidase-labeled avidin-biotin complex (Vectastain, Vector Labs, Burlingame, CA) and developed with H2O2 as substrate for diaminobenzidine as chromogen. Control tissue sections lacking antibody treatment or treated with NAAG blocked antibody exhibited no specific reaction product above background. These antibodies fail to cross react with glutamate, N-acetylaspartate, N-acetylglutamate, aspartate or GABA [48, 49]. Images were acquired on an Olympus BX51 microscope and DP71 camera, and were adjusted for contrast and brightness using PC based software (Adobe Systems). Additional software was used for enhanced depth of field by taking multiple images at different focal points in a tissue slice, and combining them into a single focused image (Media Cybernetics).
PAG and RVM cannulae placement for microinjection
Implantation of the injection cannulae into the PAG and RVM was performed under halothane anesthesia. The rats were placed in a stereotaxic apparatus (KOPF Model 900, David Kopf Instruments, CA) and stainless steel 26 G thin wall guide cannulae (C315G, PlasticsOne, One, Roanoke, VA) were stereotaxically placed at either PAG through a burr hole (AP: -7.6 mm, L: 0.7 mm, H: 6.0 mm from Bregma) or RVM through a burr hole (AP: 11.0 mm, L: 0.0 mm, H: 11.0 mm from Bregma). Guide cannulae were affixed to the skull with stainless steel screws and cranioplastic cement. 32.5 mg mefenamic acid (Daiichi-Sankyo, Tokyo, Japan) was orally administered 2 times/day at 0 – 2 days after surgery for postoperative pain control. The formalin inflammation tests were performed 7 days after cannulae implantation. All animals displayed normal feeding and drinking behaviors post-operatively. Rats showing neurological deficits after cannulae implantation were not studied.
Drugs and microinjection
The NAAG peptidase inhibitor ZJ43 (IC50 = 2.4 nM, Ki = 0.79 nM for human glutamate carboxypeptidase II ) was synthesized following methods previously described  and provided by Alan Kozikowski. LY341495, a highly selective group II metabotropic glutamate receptor antagonist , was purchased from Tocris and injected i.p. (1 mg/kg) in a total volume of 1 ml. ZJ43 and LY341495 were dissolved in saline. For the PAG and RVM microinjections, ZJ43 or saline was delivered in a total volume of 0.5 μl over a period of 60 seconds using a microsyringe pump (EP-60, Eicom) and a 30 G stainless steel internal cannula (C315G, Plastics One) connected via a polyethylene tube to a 10 μl Hamilton syringe.
At the completion of the experiment, 0.5 μl of India ink was injected into the PAG or RVM 10 min before rats were euthanized. The brains were fixed with formalin, and coronal tissue sections were Nissl stained to confirm the proper injection site. Only the rats whose microinjection site was located within PAG or RVM were included in the results.
Footpad inflammation test
In the formalin test, 50 μl of 5% formalin was injected subcutaneously (SC) into the dorsal surface of the right hind paw with a 25-gauge needle under brief halothane anesthesia. Within 1 min after the formalin injection, spontaneous flinching of the injected paw could be observed. Flinching is readily discriminated and is characterized as a rapid and brief withdrawal or flexion of the injected paw. This pain-related behavior was quantified by counting the number of flinches for 1 min periods at 1–2 and at 5–6 min, and then for 1 min periods at 5 min intervals from 10 to 60 min after the injection. Two phases of spontaneous flinching behavior were observed: an initial acute phase (phase 1: during the first 6 min after the formalin injection) and a prolonged tonic phase (phase 2: beginning about 10 min after the formalin injection).
For the dose–response studies, ZJ43 was microinjected into the PAG or RVM 10 min before the formalin injection into the footpad. In the PAG studies, the peptidase inhibitor was tested separately contralateral and ipsilateral to the injected footpad. For the PAG, 150 μg treated group: n = 7; 37.5 μg treated group: n = 5; 3.75 μg treated group: n = 6; saline: n = 6. To verify whether the effect of ZJ43 injected to PAG contralateral to the formalin injection on the formalin test was mediated by the action of ZJ43 on the site of injection, 150 μg (n = 6) of ZJ43 was administered to the PAG ipsilateral to the formalin injection 10 min before the formalin injection. For the RVM, 150 μg treated group: n = 7; 15 μg treated group: n = 5; 1.5 μg treated group: n = 5; 0.15 μg treated group: n = 5; saline: n = 7. To verify that the analgesic effect of ZJ43 in the PAG and RVM was mediated by the activation mGluR3, 1 mg/kg of LY341495 was administered (i.p.) 10 min before the microinjection of ZJ43 (150 μg) into the PAG (n = 7) or RVM (n = 10).
Hot plate test
Rats were placed on a 52.5°C surface. The response latency to either a hind-paw lick or a jump was recorded. In the absence of a response, animals were removed from the 52.5°C hot plate at 60 sec (cut-off time) and a 60 sec latency was assigned as the response.
Three baseline measurements were made before the drug injection. ZJ43 (150 μg) was administered into PAG (n = 4) or RVM (n = 4) and the hot-plate latency was measured at 5, 15, 30, 45 and 60 min after the drug injection. To obtain control data, the vehicle was injected into PAG (n = 6) or RVM (n = 4).
Microdialysis and assay of glutamate and NAAG levels
Rats were anesthetized with Ketamine (80 mg/kg)/Xylazine (5 mg/kg) (i.p.) and placed in a stereotaxic apparatus (KOPF Inc., Tujunga, CA, USA) for surgical implantation of a guide cannula. The guide cannula (SciPro Inc., Sanborn, NY, USA) was positioned to the (contralateral) PAG according to the coordinates (AP, - 7.8; ML, -0.7; DV, -4.4) or RVM according to the coordinates (AP, - 11.0; ML, -0.7; DV, -9.0). The guide cannula was secured to the skull with dental cement anchored by two stainless steel screws. After surgery, each rat was individually housed and allowed to recover for 24 hours before microdialysis and footpad injection.
Microdialysis was carried out on conscious, freely moving rats. Rats were lightly anesthetized with isofluorane to facilitate manual insertion of the microdialysis probe into the guide cannula. The stylet in the guide cannula was replaced with the microdialysis probe (outer diameter, 0.6 mm; exposed tip, 2.0 mm; cut-off of 6 kDa; SciPro Inc., Sanborn, NY, USA). The rats were tethered to the awake animal system by means of a plastic collar (CMA Microdialysis AB, Sweden). The probe was perfused at 2 μl/min with artificial cerebrospinal fluid (CMA Microdialysis AB, Sweden). After at least 2 h to reach equilibration, dialysate samples were collected every 20 min. Three baseline fractions were collected before ZJ43 or saline injection. Pretreatment of ZJ43 (150 mg/kg i.p.) or saline occurred 15 min before injecting formalin (5%, 50 μl) into the dorsal side of the left hind-paw during microdialysis. Samples were subsequently analyzed for NAAG and glutamate. At the completion of each experiment, rats were euthanized and brains were removed, fixed in 10% formalin and 30 μm coronal sections prepared to confirm probe placement.
NAAG and glutamate analysis
Glutamate in the microdialysate samples was derivatized with o-phthalaldehyde (OPA, Sigma, USA) and resolved by reverse phase HPLC (Atlantis T3, ODS, 4.6 × 150 mm, 3 μm) and electrochemical detection (Waters). Quantification was obtained from standard curves prepared over a glutamate range of 0.1–100 μM. Dialysate samples were analyzed for NAAG content using radioimmunoassay as previously described  with minor modifications. Briefly, 20 μl samples diluted to 50 μl with PBS were incubated overnight at 4°C with 25 μl of NAAG antisera (1:25) and 25 μl of 3 H]-NAAG (50,000 cpm, approximately 5 pmol). After incubation, 900 μl of −20°C methanol was added, precipitated proteins were separated by sedimentation at 15,000 x g for 15 min and tritium in the pellet and supernatant was quantified. 3 H]-NAAG bound to antibody in unknown samples was compared to that of a standard curve (0.033–3.3 μM NAAG) that was repeated with each assay.
The time-response data are presented as the mean flinches (± SEM) per minute for the periods of 1–2 min and 5–6 min and then for 1 min periods at 5 min intervals up to 60 min. For the dose–response analysis, data from phase 1 (0–2 min) and phase 2 (10–60 min) observations were considered separately. In each case, the cumulative instances of formalin-evoked flinches during the phase 1 and phase 2 were calculated for each rat. These individual rat data were then used to construct phase 1 and phase 2 dose–response curves. For dose–response data and tests of the efficacy of LY341495, one-way ANOVA was used with Tukey post-hoc test.
For the analysis of drug effect, the % maximum possible effect was calculated, where % maximum possible effect = ([post-drug maximum latency – pre-drug latency]/[cut-off time (60 sec) – pre-drug latency]) x 100. The post drug maximum latency was defined as the single longest latency during the entire time course of the hot plate test. To analyze the effect of ZJ43 on % maximum possible effect, an unpaired t-test was used.
Microdialysis data are expressed as percentage of basal values (calculated as means of the three samples before injections). Data on the responses following ZJ43 injection in the ipsilateral versus contralateral PAG were compared using Students t-test. The basal concentrations of NAAG and glutamate in the dialysates, uncorrected for recovery, were 0.053 ± 0.006 μM and 1.25 ± 0.13 μM in PAG, 0.074 ± 0.005 μM and 0.82 ± 0.07 μM in RVM respectively. The values were expressed as a % of baseline level for each rat and the mean and standard error were determined for each treatment group. Two-factor ANOVA for repeated measurements was used to examine the possibility of significant differences (p <0.05) between groups followed by Tukey post hoc test.
Microdialysis data are expressed as percentage of basal values calculated independently for each animal as mean of the three samples taken before injections. All data were given as mean ± standard error of the mean (S.E.M.) and not corrected for ‘recovery’ of the dialysis procedure. General Linear Model with repeated measurements (SPSS19 for Windows) was used to examine the possibility of significant differences (p < 0.05) between groups followed by a Student’s t-test for every time-point.
Is a NAAG peptidase Inhibitor
Is the NAAG receptor (metabotropic glutamate receptor 3)
Is an mGluR2/3 agonist
Is periaqueductal gray
Is Rostral Ventromedial Medulla
Is raphe magnus.
Chiechio S, Nicoletti F: Metabotropic glutamate receptors and the control of chronic pain. Curr Opin Pharmacol 2012, 12: 28–34. 10.1016/j.coph.2011.10.010
Wozniak KM, Rojas C, Wu Y, Slusher BS: The role of glutamate signaling in pain processes and its regulation by GCP II inhibition. Curr Med Chem 2012, 19: 1323–1334. 10.2174/092986712799462630
Neale JH, Olszewski RT, Zuo D, Janczura KJ, Profaci CP, Lavin KM, Madore JC, Bzdega T: Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family. J Neurochem 2011, 118: 490–498. 10.1111/j.1471-4159.2011.07338.x
Yamamoto T, Nozaki-Taguchi N, Sakashita Y, Inagaki T: Inhibition of spinal N-acetylated-alpha-linked acidic dipeptidase produces an antinociceptive effect in the rat formalin test. Neuroscience 2001, 102: 473–479. 10.1016/S0306-4522(00)00502-9
Yamamoto T, Nozaki-Taguchi N, Sakashita Y: Spinal N-acetyl-alpha-linked acidic dipeptidase (NAALADase) inhibition attenuates mechanical allodynia induced by paw carrageenan injection in the rat. Brain Res 2001, 909: 138–144. 10.1016/S0006-8993(01)02650-6
Yamamoto T, Hirasawa S, Wroblewska B, Grajkowska E, Zhou J, Kozikowski A, Wroblewski J, Neale JH: Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model. Eur J Neurosci 2004, 20: 483–494. 10.1111/j.1460-9568.2004.03504.x
Yamamoto T, Kozikowski A, Zhou J, Neale JH: Intracerebroventricular administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in inflammatory pain. Mol Pain 2008, 4: 31. 10.1186/1744-8069-4-31
Yamamoto T, Saito O, Aoe T, Bartolozzi A, Sarva J, Zhou J, Kozikowski A, Wroblewska B, Bzdega T, Neale JH: Local administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats. Eur J Neurosci 2007, 25: 147–158. 10.1111/j.1460-9568.2006.05272.x
Zhang W, Murakawa Y, Wozniak KM, Slusher B, Sima AA: The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy. J Neurol Sci 2006, 247: 217–223. 10.1016/j.jns.2006.05.052
Neale JH, Bzdega T, Wroblewska B: N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. J Neurochem 2000, 75: 443–452.
Neale JH: N-Acetylaspartylglutamate (NAAG) IS an agonist at mGluR3 in Vivo and in Vitro. J Neurochem 2011, 119: 891–895. 10.1111/j.1471-4159.2011.07380.x
Wroblewska B, Wegorzewska IN, Bzdega T, Neale JH: Type 2 metabotropic glutamate receptor (mGluR2) fails to negatively couple to cGMP in stably transfected cells. Neurochem Int 2011, 58: 176–179. 10.1016/j.neuint.2010.11.012
Wroblewska B, Wroblewski JT, Pshenichkin S, Surin A, Sullivan SE, Neale JH: N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J Neurochem 1997, 69: 174–181.
Wroblewska B, Wegorzewska IN, Bzdega T, Olszewski RT, Neale JH: Differential negative coupling of type 3 metabotropic glutamate receptor to cyclic GMP levels in neurons and astrocytes. J Neurochem 2006, 96: 1071–1077. 10.1111/j.1471-4159.2005.03569.x
Wroblewska B, Santi MR, Neale JH: N-acetylaspartylglutamate activates cyclic AMP-coupled metabotropic glutamate receptors in cerebellar astrocytes. Glia 1998, 24: 172–179. 10.1002/(SICI)1098-1136(199810)24:2<172::AID-GLIA2>3.0.CO;2-6
Adedoyin MO, Vicini S, Neale JH: Endogenous N-acetylaspartylglutamate (NAAG) inhibits synaptic plasticity/transmission in the amygdala in a mouse inflammatory pain model. Mol Pain 2010, 6: 60.
Sanabria ER, Wozniak KM, Slusher BS, Keller A: GCP II (NAALADase) inhibition suppresses mossy fiber-CA3 synaptic neurotransmission by a presynaptic mechanism. J Neurophysiol 2004, 91: 182–193.
Zhao J, Ramadan E, Cappiello M, Wroblewska B, Bzdega T, Neale JH: NAAG inhibits KCl-induced [(3)H]-GABA release via mGluR3, cAMP, PKA and L-type calcium conductance. Eur J Neurosci 2001, 13: 340–346.
Zhong C, Zhao X, Van KC, Bzdega T, Smyth A, Zhou J, Kozikowski AP, Jiang J, O’Connor WT, Berman RF, Neale JH, Lyeth BG: NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat. J Neurochem 2006,97(4):1015–1025. 10.1111/j.1471-4159.2006.03786.x
Zuo D, Bzdega T, Olszewski RT, Moffett JR, Neale JH: Effects of NAAG peptidase inhibition on release of glutamate and dopamine in the prefrontal cortex and nucleus accumbens in the phencyclidine model of schizophrenia. J Biol Chem 2012. E-pub ahead of print May 8, 2012
Bzdega T, Turi T, Wroblewska B, She D, Chung HS, Kim H, Neale JH: Molecular cloning of a peptidase against N-acetylaspartylglutamate from a rat hippocampal cDNA library. J Neurochem 1997, 69: 2270–2277.
Bzdega T, Crowe SL, Ramadan ER, Sciarretta KH, Olszewski RT, Ojeifo OA, Rafalski VA, Wroblewska B, Neale JH: The cloning and characterization of a second brain enzyme with NAAG peptidase activity. J Neurochem 2004, 89: 627–635. 10.1111/j.1471-4159.2004.02361.x
Carter RE, Feldman AR, Coyle JT: Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 1996, 93: 749–753. 10.1073/pnas.93.2.749
Israeli RS, Powell CT, Fair WR, Heston WD: Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993, 53: 227–230.
Luthi-Carter R, Berger UV, Barczak AK, Enna M, Coyle JT: Isolation and expression of a rat brain cDNA encoding glutamate carboxypeptidase II. Proc Natl Acad Sci USA 1998, 95: 3215–3220. 10.1073/pnas.95.6.3215
Tsukamoto T, Wozniak KM, Slusher BS: Progress in the discovery and development of glutamate carboxypeptidase II inhibitors. Drug Discov Today 2007, 12: 767–776. 10.1016/j.drudis.2007.07.010
Zhou J, Neale JH, Pomper MG, Kozikowski AP: NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov 2005, 4: 1015–1026. 10.1038/nrd1903
Kozikowski AP, Zhang J, Nan F, Petukhov PA, Grajkowska E, Wroblewski JT, Yamamoto T, Bzdega T, Wroblewska B, Neale JH: Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J Med Chem 2004, 47: 1729–1738. 10.1021/jm0306226
Saito O, Aoe T, Kozikowski A, Sarva J, Neale JH, Yamamoto T: Ketamine and N-acetylaspartylglutamate peptidase inhibitor exert analgesia in bone cancer pain. Can J Anaesth 2006, 53: 891–898. 10.1007/BF03022832
Williamson LC, Neale JH: Ultrastructural localization of N-acetylaspartylglutamate in synaptic vesicles of retinal neurons. Brain Res 1988, 456: 375–381. 10.1016/0006-8993(88)90243-0
Moffett JR: Reductions in N-acetylaspartylglutamate and the 67 kDa form of glutamic acid decarboxylase immunoreactivities in the visual system of albino and pigmented rats after optic nerve transections. J Comp Neurol 2003, 458: 221–239. 10.1002/cne.10570
Moffett JR, Williamson LC, Neale JH, Palkovits M, Namboodiri MA: Effect of optic nerve transection on N-acetylaspartylglutamate immunoreactivity in the primary and accessory optic projection systems in the rat. Brain Res 1991, 538: 86–94. 10.1016/0006-8993(91)90380-E
Neale JH, Olszewski RT, Gehl LM, Wroblewska B, Bzdega T: The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. Trends Pharmacol Sci 2005, 26: 477–484.
Maione S, Oliva P, Marabese I, Palazzo E, Rossi F, Berrino L, Filippelli A: Periaqueductal gray matter metabotropic glutamate receptors modulate formalin-induced nociception. Pain 2000, 85: 183–189. 10.1016/S0304-3959(99)00269-9
Ohishi H, Shigemoto R, Nakanishi S, Mizuno N: Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. J Comp Neurol 1993, 335: 252–266. 10.1002/cne.903350209
Fields HL, Heinricher MM, Mason P: Neurotransmitters in nociceptive modulatory circuits. Annu Rev Neurosci 1991, 14: 219–245. 10.1146/annurev.ne.14.030191.001251
de Novellis V, Marabese I, Uliano R, Palazzo E, Scafuro A, sca Rossi F, Maione S: Type I and II metabotropic glutamate receptors modulate periaqueductal grey glycine release: interaction between mGlu2/3 and A1 adenosine receptors. Neuropharmacology 2002, 43: 1061–1069. 10.1016/S0028-3908(02)00227-7
Drew GM, Vaughan CW: Multiple metabotropic glutamate receptor subtypes modulate GABAergic neurotransmission in rat periaqueductal grey neurons in vitro. Neuropharmacology 2004, 46: 927–934. 10.1016/j.neuropharm.2004.01.015
Cho HJ, Basbaum AI: GABAergic circuitry in the rostral ventral medulla of the rat and its relationship to descending antinociceptive controls. J Comp Neurol 1991,303(2):316–328. 10.1002/cne.903030212
da Silva LF, Coutinho MR, Menescal-de-Oliveira L: Opioidergic and GABAergic mechanisms in the rostral ventromedial medulla modulate the nociceptive response of vocalization in guinea pigs. Brain Res Bull 2010, 82: 177–183. 10.1016/j.brainresbull.2010.04.002
Fell MJ, Svensson KA, Johnson BG, Schoepp DD: Evidence for the role of metabotropic glutamate (mGlu)2 not mGluR3 receptors in the preclinical antipsychotic pharmacology of the mGluR2/3 receptor agonist (−)-(1R, 4 S, 5 S, 6 S)-4-amino-2sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther 2008, 326: 209–217. 10.1124/jpet.108.136861
Woolley ML, Pemberton DJ, Bate S, Corti C, Jones DN: The mGluR2 but not the mGluR3 receptor mediates the actions of the mGluR2/3 agonist, LY3799268, in mouse models predictive of antipsychotic activity. Psychopharmacology 2008, 196: 431–434. 10.1007/s00213-007-0974-x
Olszewski RT, Bzdega T, Neale JH: mGluR3 and not mGluR2 Receptors Mediate the Efficacy of NAAG Peptidase Inhibitor in PCP Model of Schizophrenia. Schizophr Res 2012, 136: 160–161. 10.1016/j.schres.2012.01.007
Bacich DJ, Ramadan E, O’Keefe DS, Bukhari N, Wegorzewska I, Ojeifo O, Olszewski R, Wrenn CC, Bzdega T, Wroblewska B, Heston WD, Neale JH: Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N-acetylaspartylglutamate. J Neurochem 2002, 83: 20–29. 10.1046/j.1471-4159.2002.01117.x
Ghadge GD, Slusher BS, Bodner A, Canto MD, Wozniak K, Thomas AG, Rojas C, Tsukamoto T, Majer P, Miller RJ, Monti AL, Roos RP: Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci USA 2003, 100: 9554–9559. 10.1073/pnas.1530168100
Profaci CP, Krolikowski KA, Olszewski RT, Neale JH: Group II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and D-amphetamine models of schizophrenia. Psychopharmacology (Berl) 2011, 216: 235–43. 10.1007/s00213-011-2200-0
Fuhrman S, Palkovits M, Cassidy M, Neale JH: The regional distribution of N-acetylaspartylglutamate (NAAG) and peptidase activity against NAAG in the rat nervous system. J Neurochem 1994, 62: 275–281.
Moffett JR, Namboodiri MA: Differential distribution of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat forebrain. J Neurocytol 1995, 24: 409–433. 10.1007/BF01181604
Moffett JR, Namboodiri MA, Neale JH: Enhanced carbodiimide fixation for immunohistochemistry: application to the comparative distributions of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat brain. J Histochem Cytochem 1993,41(4):559–570. 10.1177/41.4.8450195
Kingston AE, Ornstein PL, Wright RA, Johnson BG, Mayne NG, Burnett JP, Belagaje R, Wu S, Schoepp DD: LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology 1998, 37: 1–12. 10.1016/S0028-3908(97)00191-3
This work was supported by a grant from NIH (NS38080) to JHN. Nancy and Daniel Paduano also provided generous support for this research. D Z was supported by the China Scholarship Council-Georgetown University Fellowship Program. We thank Gerard Ahern for thoughtful comments on an early version of the manuscript.
Georgetown University holds the patent rights to ZJ43. The authors have no interests in this patent. Authors have no commercial associations that might pose a conflict of interest in connection with the submitted article.
JM performed immunohistochemistry; JN designed the research and wrote the manuscript; TY designed and directed the research; TY executed the microinjection studies; DZ executed the microdialysis studies; RO assisted with the RIA of NAAG, assembled and edited the manuscript; TB assisted with the HPLC and analysis of glutamate and dopamine, edited the manuscript. All authors read and approved the final manuscript.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Yamada, T., Zuo, D., Yamamoto, T. et al. NAAG peptidase inhibition in the periaqueductal gray and rostral ventromedial medulla reduces flinching in the formalin model of inflammation. Mol Pain 8, 67 (2012) doi:10.1186/1744-8069-8-67
- Inflammatory pain